Tran Bach Xuan, Nguyen Long Hoang, Ohinmaa Arto, Maher Rachel Marie, Nong Vuong Minh, Latkin Carl A
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Institute for Preventive Medicine and Public Health, Hanoi Medical University, Hanoi, Vietnam.
BMC Health Serv Res. 2015 Jan 22;15:7. doi: 10.1186/s12913-014-0640-z.
Utility estimates are important health outcomes for economic evaluation of care and treatment interventions for patients with HIV/AIDS. We conducted a systematic review and meta-analysis of utility measurements to examine the performance of preference-based instruments, estimate health utility of patients with HIV/AIDS by disease stages, and investigate changes in their health utility over the course of antiretroviral treatment.
We searched PubMed/Medline, Cochrane Database of Systematic Review, NHS Economic Evaluation Database and Web of Science for English-language peer-reviewed papers published during 2000-2013. We selected 49 studies that used 3 direct and 6 indirect preference based instruments to make a total of 218 utility measurements. Random effect models with robust estimation of standard errors and multivariate fractional polynomial regression were used to obtain the pooled estimates of utility and model their trends.
Reliability of direct-preference measures tended to be lower than other types of measures. Utility elicited by two of the indirect preference measures - SF-6D (0.171) and EQ-5D (0.114), and that of Time-Trade off (TTO) (0.151) was significantly different than utility elicited by Standard Gamble (SG). Compared to asymptomatic HIV patients, symptomatic and AIDS patients reported a decrement of 0.025 (p = 0.40) and 0.176 (p = 0.001) in utility scores, adjusting for method of assessment. In longitudinal studies, the pooled health utility of HIV/AIDS patients significantly decreased in the first 3 months of treatment, and rapidly increased afterwards. Magnitude of change varied depending on the method of assessment and length of antiretroviral treatment.
The study provides an accumulation of evidence on measurement properties of health utility estimates that can help inform the selection of instruments for future studies. The pooled estimates of health utilities and their trends are useful in economic evaluation and policy modelling of HIV/AIDS treatment strategies.
效用估计是对艾滋病毒/艾滋病患者护理和治疗干预措施进行经济评估的重要健康结果。我们对效用测量进行了系统评价和荟萃分析,以检验基于偏好的工具的性能,按疾病阶段估计艾滋病毒/艾滋病患者的健康效用,并调查他们在抗逆转录病毒治疗过程中的健康效用变化。
我们在PubMed/Medline、Cochrane系统评价数据库、NHS经济评价数据库和科学网中检索了2000年至2013年期间发表的英文同行评审论文。我们选择了49项研究,这些研究使用了3种直接和6种间接基于偏好的工具,共进行了218次效用测量。采用具有稳健标准误差估计的随机效应模型和多元分数多项式回归来获得效用的合并估计值并对其趋势进行建模。
直接偏好测量的可靠性往往低于其他类型的测量。两种间接偏好测量方法——SF-6D(0.171)和EQ-5D(0.114)以及时间权衡法(TTO)(0.151)得出的效用与标准博弈法(SG)得出的效用显著不同。在调整评估方法后,与无症状艾滋病毒患者相比,有症状患者和艾滋病患者的效用得分分别下降了0.025(p = 0.40)和0.176(p = 0.001)。在纵向研究中,艾滋病毒/艾滋病患者的合并健康效用在治疗的前3个月显著下降,之后迅速上升。变化幅度因评估方法和抗逆转录病毒治疗时间长短而异。
该研究积累了关于健康效用估计测量特性的证据,有助于为未来研究的工具选择提供参考。健康效用的合并估计值及其趋势在艾滋病毒/艾滋病治疗策略的经济评估和政策建模中很有用。